View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 2, 2020

Relief Therapeutics doses patients in Phase IIb/III study for ARDS in Covid-19

By Allie Nawrat

Relief Therapeutics and its partner NeuroRx have initiated dosing of its Phase IIb/III trial of RLF-100 for acute respiratory distress syndrome (ARDS) in Covid-19 patients who are on mechanical ventilation.

RLF-100 is a synthetic human vasoactive intestinal polypeptide (VIP). In animal models, VIP has been shown to inhibit inflammatory cytokines and protect pulmonary epithelial cells in the lungs.

Principal study investigator at the University of Miami, Dushyantha T Jayaweera commented: “ARDS is the primary cause of COVID-19 related deaths triggered by acute inflammation in the air sacs (alveolae) of the lungs.

“There is an urgent need for a treatment that can specifically protect type 2 alveolar cells and suppress excessive inflammation.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology